查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
連續生物加工的全球市場：按產品、過程、營運規模、應用和最終用戶 - 預測（～2028年）
市場調查報告書
商品編碼
1393002

連續生物加工的全球市場：按產品、過程、營運規模、應用和最終用戶 - 預測（～2028年）

Continuous Bioprocessing Market by Product, Process, Scale of Operation, Application, & End User - Global Forecast to 2028
出版日期: | 出版商: MarketsandMarkets | 英文 263 Pages | 訂單完成後即時交付

價格
簡介目錄

報告概述

調查範圍
調查年份 2021-2028
基準年 2022年
預測期 2023-2028
單位 100萬美元
區隔 產品、營運規模、流程、應用、最終用戶
目標區域 北美、歐洲、亞太地區、拉丁美洲、中東、非洲

全球連續生物加工市場規模預計到2023年將達到 2.18 億美元，到2028年將達到 5.99 億美元，2023-2028年預測期間年複合成長率為 22.4%。

市場成長歸因於 CDMO 和 CMO 連續生物加工的日益採用。連續生物加工在生物製藥生產的 CDMO 和 CMO 中越來越普及。這些組織面臨越來越大的壓力，需要更快、更有效率地製造生物製藥，而連續生物加工可以幫助滿足這項需求。此外，連續生物加工進入更大規模的計劃和新的治療領域。預計這一趨勢將在未來幾年推動連續生物加工市場的成長。

「從應用來看，單株抗體細分市場在2022年佔據最大佔有率。」

連續生物加工在單株抗體生物加工領域迅速發展，具有設備佔地面積小、投資成本低、彈性和製程經濟性等潛在優勢。哺乳動物細胞單株抗體在商業性的成功導致對新型一次性生物反應器系統的需求增加，這些系統可提供更高的生產率、彈性並降低成本。

「在2023-2028年預測期內，美國將繼續主導市場。」

美國是生物製藥的主導市場，約佔全球市場的三分之一。它也是生物製藥研發領域的世界領導者。根據美國研究與製藥工業協會（PhRMA）的資料，美國製藥公司持有大多數新藥的智慧財產權，並進行了全球一半以上的藥物研發。美國生物加工公司正積極參與利用連續生物加工技術開發生物製藥。這些公司還提供各種基於灌注的產品，這些產品週轉時間短且節能。這些因素支持該國連續生物加工市場的成長。

本報告研究和分析了全球連續生物加工市場，提供了關鍵促進因素和抑制因素、競爭形勢和未來趨勢資訊。

目錄

第1章 簡介

第2章 調查方法

第3章 執行摘要

第4章 重要考察

  • 連續生物加工市場概述
  • 北美連續生物加工市場：依產品
  • 連續生物加工市場：依應用分類
  • 連續生物加工市場：地理成長機會

第5章 市場概況

  • 介紹
  • 市場動態
    • 促進因素
    • 抑制因素
    • 機會
    • 課題
  • 價格分析
  • 影響客戶業務的趨勢/干擾
  • 價值鏈分析
    • 研究/產品開發
    • 原料、製造、組裝
    • 銷售、售後服務
  • 供應鏈分析
  • 生態系分析
  • 專利分析
  • 重大會議及活動
  • 監管形勢
    • 監管機構、政府機構和其他組織
    • 監管指引
  • 波特五力分析
  • 技術分析
  • 主要利害關係人和採購標準
  • 主要購買標準：依最終用戶

第6章 連續生物加工市場：依產品

  • 介紹
  • 層析法系統、消耗品
  • 過濾系統和設備
  • 生物反應器
  • 細胞培養基、細胞株、緩衝液和試劑
  • 其他產品

第7章 連續生物加工市場：依營運規模

  • 介紹
  • 商業運作
  • 臨床操作

第8章 連續生物加工市場：依製程分類

  • 介紹
  • 下游生物過程
  • 上游生物程序

第9章 連續生物加工市場：依應用分類

  • 介紹
  • 單株抗體
  • 疫苗
  • 細胞/基因治療
  • 其他用途

第10章 連續生物加工市場：依最終用戶分類

  • 介紹
  • 製藥公司、生技公司
  • 委外研發機構（CRO）、受託製造廠商（CMO）
  • 學術/研究機構

第11章 連續生物加工市場：依地區

  • 介紹
  • 北美洲
    • 美國
    • 加拿大
    • 北美經濟衰退的影響
  • 歐洲
    • 德國
    • 英國
    • 法國
    • 義大利
    • 西班牙
    • 歐洲其他地區
    • 歐洲經濟衰退的影響
  • 亞太地區
    • 中國
    • 日本
    • 印度
    • 韓國
    • 其他亞太地區
    • 亞太地區經濟衰退的影響
  • 拉丁美洲
    • 巴西
    • 墨西哥
    • 其他拉丁美洲
    • 拉丁美洲經濟衰退的影響
  • 中東、非洲
    • 中東
    • 非洲
    • 中東和非洲經濟衰退的影響

第12章 競爭形勢

  • 概述
  • 主要企業策略/主要企業
  • 收益佔有率分析
  • 市場佔有率分析
  • 公司評級矩陣
  • 新創公司/小型企業評估矩陣
  • 競爭格局及趨勢

第13章 公司簡介

  • 主要企業
    • DANAHER CORPORATION
    • SARTORIUS AG
    • THERMO FISHER SCIENTIFIC INC.
    • REPLIGEN CORPORATION
    • MERCK KGAA
    • 3M COMPANY
    • GETINGE AB
    • EPPENDORF SE
    • CORNING INCORPORATED
    • ENTEGRIS
    • FUJIFILM HOLDINGS CORPORATION
    • MEISSNER FILTRATION PRODUCTS, INC.
    • KUHNER AG
    • ESCO LIFESCIENCES GROUP
    • SATAKE MULTIMIX CORPORATION
  • 其他公司
    • BIONET
    • STOBBE GROUP
    • BBI-BIOTECH GMBH
    • OMNIBRX BIOTECHNOLOGIES
    • CELL CULTURE COMPANY, LLC
    • PIERRE GUERIN
    • SOLIDA BIOTECH GMBH
    • ZELLWERK GMBH
    • 3D BIOTEK, LLC
    • FIBERCELL SYSTEMS INC.

第14章 附錄

簡介目錄
Product Code: PH 8866

Report Description

Scope of the Report
Years Considered for the Study2021-2028
Base Year2022
Forecast Period2023-2028
Units ConsideredValue (USD) Million
SegmentsProduct, Scale of Operation, Process, Application & End User
Regions coveredNorth America, Europe, Asia Pacific, Latin America, and the Middle East and Africa

The global continuous bioprocessing market is projected to reach USD 599 million by 2028 from USD 218 million in 2023, at a CAGR of 22.4% during the forecast period of 2023 to 2028. The growth of this market can be attributed to the increasing adoption of continuous bioprocessing among CDMOs and CMOs. Continuous bioprocessing is becoming more popular among CDMOs and CMOs for the production of biopharmaceuticals. These organizations face increasing pressure to manufacture biopharmaceuticals faster and more efficiently, and continuous bioprocessing can help them meet this demand. Additionally, continuous bioprocessing is moving into larger-scale projects and new therapeutic areas. This trend is expected to drive the growth of the continuous bioprocessing market in the coming years.

"The monoclonal antibodies segment accounted for the largest share by application in 2022."

In 2022, the monoclonal antibodies segment accounted for the largest share by application in the global continuous bioprocessing market. Continuous bioprocessing is rapidly gaining momentum in monoclonal antibody bioprocessing, providing potential advantages such as smaller facility footprints, lower investment costs, flexibility, and process economy. The commercial success of mammalian cell-derived mAbs has led to the increased demand for novel single-use bioreactor systems that provide greater productivity & flexibility and reduce costs.

"The US has continued to dominate the continuous bioprocessing market during the forecast period of 2023-2028."

The US dominated the continuous bioprocessing market in North America in 2022. The US is the dominant market for biopharmaceuticals, accounting for around a third of the global market. It is the world leader in biopharmaceutical R&D. According to the Pharmaceutical Research and Manufacturers Association (PhRMA), US pharmaceutical firms hold the intellectual property rights for most new medicines and conduct over half the world's R&D in pharmaceuticals. Bioprocessing companies in the US are actively participating in the development of biopharmaceuticals using continuous bioprocessing. These companies are also widely offer perfusion-based products, which offer less turnaround time and are energy-efficient. These factors are supporting the growth of the continuous bioprocessing market in the country.

The primary interviews conducted for this report can be categorized as follows:

  • By Respondent: Supply Side- 70% and Demand Side 30%
  • By Designation: Managers - 45%, CXO & Directors - 30%, and Executives - 25%
  • By Region: North America -40%, Europe -25%, Asia-Pacific -20%, Latin America -10% and Middle East & Africa- 5%

List of Companies Profiled in the Report:

  • Thermo Fisher Scientific Inc. (US)
  • Danaher Corporation (US)
  • Sartorius AG (Germany)
  • Thermo Fisher Scientific Inc. (US)
  • Repligen Corporation (US)
  • Merck KGaA (Germany)
  • 3M Company (US)
  • Getinge AB (Sweden)
  • Eppendorf SE (Germany)
  • Corning Incorporated (US)
  • Entegris (US)
  • FUJIFILM Holdings Corporation (Japan)
  • Meissner filtration products, Inc. (US)
  • Kuhner AG (Switzerland)
  • Esco Lifesciences Group (Singapore)
  • SATAKE MultiMix Corporation (Japan)
  • Bionet (Spain)
  • Stobbe Group (Switzerland)
  • bbi-biotech GmbH (Germany)
  • OmniBRx Biotechnologies (India)
  • Cell Culture Company, LLC (US)
  • Pierre Guerin (France)
  • Solida Biotech GmbH (Germany)
  • Zellwerk GmbH (Germany)
  • 3D Biotek, LLC (US)
  • FiberCell Systems Inc. (US)

Research Coverage:

This research report categorizes the continuous bioprocessing market by product (chromatography systems and consumables, filtration systems and devices, bioreactors, cell culture media, cell lines, buffers and reagents, and other products), by scale of operation (commercial operations and clinical operations), by process (downstream bioprocess and upstream bioprocess), by application (monoclonal antibodies, vaccines, cell and gene therapy, and other applications), by end users (pharmaceutical & biopharmaceutical companies, contract research organizations (CROs) & contract manufacturing organizations (CMOs), and academic & research institutes) and by region (North America, Europe, Asia Pacific, Latin America, and Middle East & Africa). The scope of the report covers detailed information regarding the major factors, such as drivers, restraints, challenges, and opportunities, influencing the growth of the continuous bioprocessing market. A detailed analysis of the key industry players has been done to provide insights into their business overview, products, solutions, key strategies, collaborations, partnerships, and agreements. New launches, collaborations and acquisitions, and recent developments associated with the continuous bioprocessing market.

Key Benefits of Buying the Report:

The report will help market leaders/new entrants by providing them with the closest approximations of the revenue numbers for the overall continuous bioprocessing market and its subsegments. It will also help stakeholders better understand the competitive landscape and gain more insights to better position their business and make suitable go-to-market strategies. This report will enable stakeholders to understand the market's pulse and provide them with information on the key market drivers, restraints, opportunities, and challenges.

The report provides insights on the following pointers:

  • Analysis of key drivers (rising demand for biopharmaceuticals, growing adoption among CDMOs and CMOs, advantages of continuous bioprocessing over batch/fed-batch mode, favorable regulatory & government support for innovative technologies, and emergence of integrated end-to-end continuous bioprocessing), restraints (high capital investment to limit entry for small players and stringent regulatory requirements), opportunities (high growth potential of emerging economies and PAT-enabled optimization of continuous bioprocessing), and Challenges (integration into existing manufacturing facilities and operational challenges) influencing the growth of the market.
  • Product Development/Innovation: Detailed insights on newly launched products of the continuous bioprocessing market
  • Market Development: Comprehensive information about lucrative markets - the report analyses the market across varied regions.
  • Market Diversification: Exhaustive information about new products, untapped geographies, recent developments, and investments in the continuous bioprocessing market
  • Competitive Assessment: Danaher Corporation (US), Sartorius AG (Germany), Thermo Fisher Scientific Inc. (US), Repligen Corporation (US), Merck KGaA (Germany), 3M Company (US), Getinge AB (Sweden), Eppendorf SE (Germany), Corning Incorporated (US), Entegris (US), FUJIFILM Holdings Corporation (Japan), Meissner filtration products, Inc. (US), Kuhner AG (Switzerland), Esco Lifesciences Group (Singapore), SATAKE MultiMix Corporation (Japan), and among others in the market.

TABLE OF CONTENTS

1 INTRODUCTION

  • 1.1 STUDY OBJECTIVES
  • 1.2 MARKET DEFINITION
    • 1.2.1 INCLUSIONS AND EXCLUSIONS
  • 1.3 MARKET SEGMENTATION
    • FIGURE 1 CONTINUOUS BIOPROCESSING MARKET SEGMENTATION
  • 1.4 YEARS CONSIDERED
  • 1.5 CURRENCY CONSIDERED
  • 1.6 LIMITATIONS
  • 1.7 STAKEHOLDERS
  • 1.8 RECESSION IMPACT

2 RESEARCH METHODOLOGY

  • 2.1 RESEARCH DATA
    • FIGURE 2 RESEARCH DESIGN
    • 2.1.1 SECONDARY DATA
    • 2.1.2 PRIMARY DATA
    • FIGURE 3 CONTINUOUS BIOPROCESSING MARKET: BREAKDOWN OF PRIMARIES
  • 2.2 MARKET SIZE ESTIMATION
    • FIGURE 4 MARKET SIZE ESTIMATION: SUPPLY-SIDE ANALYSIS (2022)
    • FIGURE 5 MARKET SIZE ESTIMATION: APPROACH 1 (REVENUE SHARE ANALYSIS)
    • FIGURE 6 ILLUSTRATIVE EXAMPLE OF SARTORIUS AG: REVENUE SHARE ANALYSIS (2022)
    • 2.2.1 INSIGHTS FROM PRIMARIES
    • FIGURE 7 MARKET VALIDATION FROM PRIMARY EXPERTS
    • FIGURE 8 MARKET SIZE ESTIMATION METHODOLOGY: TOP-DOWN APPROACH
  • 2.3 GROWTH FORECAST
    • FIGURE 9 CONTINUOUS BIOPROCESSING MARKET: CAGR PROJECTIONS (2023-2028)
    • FIGURE 10 CONTINUOUS BIOPROCESSING MARKET: GROWTH ANALYSIS OF DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
  • 2.4 DATA TRIANGULATION & MARKET BREAKDOWN
    • FIGURE 11 DATA TRIANGULATION METHODOLOGY
  • 2.5 RESEARCH ASSUMPTIONS
  • 2.6 RISK ANALYSIS
  • 2.7 RECESSION IMPACT ANALYSIS
    • TABLE 1 GLOBAL INFLATION RATE PROJECTIONS, 2021-2028 (% GROWTH)
    • TABLE 2 US HEALTH EXPENDITURE, 2019-2022 (USD MILLION)
    • TABLE 3 US HEALTH EXPENDITURE, 2023-2030 (USD MILLION)

3 EXECUTIVE SUMMARY

    • FIGURE 12 CONTINUOUS BIOPROCESSING MARKET, BY PRODUCT, 2023 VS. 2028 (USD MILLION)
    • FIGURE 13 CONTINUOUS BIOPROCESSING MARKET, BY SCALE OF OPERATION, 2023 VS. 2028 (USD MILLION)
    • FIGURE 14 CONTINUOUS BIOPROCESSING MARKET, BY PROCESS, 2023 VS. 2028 (USD MILLION)
    • FIGURE 15 CONTINUOUS BIOPROCESSING MARKET, BY APPLICATION, 2023 VS. 2028 (USD MILLION)
    • FIGURE 16 CONTINUOUS BIOPROCESSING MARKET, BY END USER, 2023 VS. 2028 (USD MILLION)
    • FIGURE 17 GEOGRAPHICAL SNAPSHOT OF CONTINUOUS BIOPROCESSING MARKET

4 PREMIUM INSIGHTS

  • 4.1 CONTINUOUS BIOPROCESSING MARKET OVERVIEW
    • FIGURE 18 RISING DEMAND FOR BIOPHARMACEUTICALS TO DRIVE MARKET GROWTH DURING FORECAST PERIOD
  • 4.2 NORTH AMERICA: CONTINUOUS BIOPROCESSING MARKET, BY PRODUCT
    • FIGURE 19 CHROMATOGRAPHY SYSTEMS & CONSUMABLES SEGMENT ACCOUNTED FOR LARGEST MARKET SHARE IN 2022
  • 4.3 CONTINUOUS BIOPROCESSING MARKET, BY APPLICATION
    • FIGURE 20 MONOCLONAL ANTIBODIES SEGMENT TO DOMINATE MARKET DURING FORECAST PERIOD
  • 4.4 CONTINUOUS BIOPROCESSING MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES
    • FIGURE 21 CHINA TO REGISTER HIGHEST GROWTH RATE DURING FORECAST PERIOD

5 MARKET OVERVIEW

  • 5.1 INTRODUCTION
    • FIGURE 22 CONTINUOUS BIOPROCESSING MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
  • 5.2 MARKET DYNAMICS
    • TABLE 4 CONTINUOUS BIOPROCESSING MARKET: IMPACT ANALYSIS
    • 5.2.1 DRIVERS
      • 5.2.1.1 Rising demand for biopharmaceuticals
      • 5.2.1.2 Growing adoption among CDMOs and CMOs
      • 5.2.1.3 Advantages of continuous bioprocessing over batch/fed-batch mode
      • 5.2.1.4 Favorable regulatory & government support for innovative technologies
      • 5.2.1.5 Emergence of integrated end-to-end continuous bioprocessing
    • 5.2.2 RESTRAINTS
      • 5.2.2.1 High capital investments to limit entry for smaller players
      • 5.2.2.2 Stringent regulatory requirements
    • 5.2.3 OPPORTUNITIES
      • 5.2.3.1 High growth potential of emerging economies
      • 5.2.3.2 PAT-enabled optimization of continuous bioprocessing
    • 5.2.4 CHALLENGES
      • 5.2.4.1 Integration into existing manufacturing facilities
      • 5.2.4.2 Operational challenges
  • 5.3 PRICING ANALYSIS
    • TABLE 5 AVERAGE SELLING PRICE OF CONTINUOUS BIOPROCESSING PRODUCTS, BY KEY PLAYER (2022)
    • TABLE 6 AVERAGE SELLING PRICE OF CONTINUOUS BIOPROCESSING PRODUCTS, BY REGION (2022)
  • 5.4 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS' BUSINESSES
    • FIGURE 23 REVENUE SHIFT AND NEW POCKETS FOR CONTINUOUS BIOPROCESSING PRODUCT PROVIDERS
  • 5.5 VALUE CHAIN ANALYSIS
    • FIGURE 24 CONTINUOUS BIOPROCESSING MARKET: VALUE CHAIN ANALYSIS
    • 5.5.1 RESEARCH & PRODUCT DEVELOPMENT
    • 5.5.2 RAW MATERIAL, MANUFACTURING, AND ASSEMBLY
    • 5.5.3 DISTRIBUTION AND AFTER-SALES SERVICES
  • 5.6 SUPPLY CHAIN ANALYSIS
    • FIGURE 25 CONTINUOUS BIOPROCESSING MARKET: SUPPLY CHAIN ANALYSIS
  • 5.7 ECOSYSTEM ANALYSIS
    • FIGURE 26 ECOSYSTEM MARKET MAP: CONTINUOUS BIOPROCESSING MARKET
    • TABLE 7 CONTINUOUS BIOPROCESSING MARKET: ROLE IN ECOSYSTEM (SUPPLY/DEMAND SIDE)
  • 5.8 PATENT ANALYSIS
    • FIGURE 27 PATENT APPLICATIONS FOR CONTINUOUS BIOPROCESSING MARKET (JANUARY 2013-SEPTEMBER 2023)
  • 5.9 KEY CONFERENCES AND EVENTS
    • TABLE 8 CONTINUOUS BIOPROCESSING MARKET: DETAILED LIST OF CONFERENCES AND EVENTS (2023-2024)
  • 5.10 REGULATORY LANDSCAPE
    • 5.10.1 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
    • TABLE 9 NORTH AMERICA: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
    • TABLE 10 EUROPE: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
    • TABLE 11 ASIA PACIFIC: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
    • TABLE 12 REST OF THE WORLD: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
    • 5.10.2 REGULATORY GUIDELINES
  • 5.11 PORTER'S FIVE FORCES ANALYSIS
    • TABLE 13 CONTINUOUS BIOPROCESSING MARKET: PORTER'S FIVE FORCES ANALYSIS
    • 5.11.1 THREAT OF NEW ENTRANTS
    • 5.11.2 THREAT OF SUBSTITUTES
    • 5.11.3 BARGAINING POWER OF SUPPLIERS
    • 5.11.4 BARGAINING POWER OF BUYERS
    • 5.11.5 INTENSITY OF COMPETITIVE RIVALRY
  • 5.12 TECHNOLOGY ANALYSIS
  • 5.13 KEY STAKEHOLDERS AND BUYING CRITERIA
    • FIGURE 28 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS FOR CONTINUOUS BIOPROCESSING PRODUCTS
  • 5.14 KEY BUYING CRITERIA, BY END USER
    • FIGURE 29 KEY BUYING CRITERIA OF END USERS IN CONTINUOUS BIOPROCESSING MARKET

6 CONTINUOUS BIOPROCESSING MARKET, BY PRODUCT

  • 6.1 INTRODUCTION
    • TABLE 14 CONTINUOUS BIOPROCESSING MARKET, BY PRODUCT, 2021-2028 (USD MILLION)
  • 6.2 CHROMATOGRAPHY SYSTEMS AND CONSUMABLES
    • 6.2.1 ADVANTAGES OF HIGH PRODUCTIVITY AND AFFORDABILITY TO DRIVE MARKET
    • TABLE 15 CHROMATOGRAPHY SYSTEMS AND CONSUMABLES MARKET, BY REGION, 2021-2028 (USD MILLION)
    • TABLE 16 NORTH AMERICA: CHROMATOGRAPHY SYSTEMS AND CONSUMABLES MARKET, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 17 EUROPE: CHROMATOGRAPHY SYSTEMS AND CONSUMABLES MARKET, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 18 ASIA PACIFIC: CHROMATOGRAPHY SYSTEMS AND CONSUMABLES MARKET, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 19 LATIN AMERICA: CHROMATOGRAPHY SYSTEMS AND CONSUMABLES MARKET, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 20 MIDDLE EAST & AFRICA: CHROMATOGRAPHY SYSTEMS AND CONSUMABLES MARKET, BY REGION, 2021-2028 (USD MILLION)
  • 6.3 FILTRATION SYSTEMS AND DEVICES
    • 6.3.1 RISING TECHNOLOGICAL ADVANCEMENTS IN FILTRATION SYSTEMS TO DRIVE MARKET
    • TABLE 21 FILTRATION SYSTEMS AND DEVICES MARKET, BY REGION, 2021-2028 (USD MILLION)
    • TABLE 22 NORTH AMERICA: FILTRATION SYSTEMS AND DEVICES MARKET, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 23 EUROPE: FILTRATION SYSTEMS AND DEVICES MARKET, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 24 ASIA PACIFIC: FILTRATION SYSTEMS AND DEVICES MARKET, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 25 LATIN AMERICA: FILTRATION SYSTEMS AND DEVICES MARKET, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 26 MIDDLE EAST & AFRICA: FILTRATION SYSTEMS AND DEVICES MARKET, BY REGION, 2021-2028 (USD MILLION)
  • 6.4 BIOREACTORS
    • 6.4.1 ABILITY TO ENABLE PROCESS INTENSIFICATION TO BOOST DEMAND
    • TABLE 27 BIOREACTORS MARKET, BY REGION, 2021-2028 (USD MILLION)
    • TABLE 28 NORTH AMERICA: BIOREACTORS MARKET, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 29 EUROPE: BIOREACTORS MARKET, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 30 ASIA PACIFIC: BIOREACTORS MARKET, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 31 LATIN AMERICA: BIOREACTORS MARKET, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 32 MIDDLE EAST & AFRICA: BIOREACTORS MARKET, BY REGION, 2021-2028 (USD MILLION)
  • 6.5 CELL CULTURE MEDIA, CELL LINES, BUFFERS, AND REAGENTS
    • 6.5.1 INNOVATIONS IN CELL LINE DEVELOPMENT TO SUPPORT MARKET GROWTH
    • TABLE 33 CELL CULTURE MEDIA, CELL LINES, BUFFERS, AND REAGENTS MARKET, BY REGION, 2021-2028 (USD MILLION)
    • TABLE 34 NORTH AMERICA: CELL CULTURE MEDIA, CELL LINES, BUFFERS, AND REAGENTS MARKET, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 35 EUROPE: CELL CULTURE MEDIA, CELL LINES, BUFFERS, AND REAGENTS MARKET, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 36 ASIA PACIFIC: CELL CULTURE MEDIA, CELL LINES, BUFFERS, AND REAGENTS MARKET, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 37 LATIN AMERICA: CELL CULTURE MEDIA, CELL LINES, BUFFERS, AND REAGENTS MARKET, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 38 MIDDLE EAST & AFRICA: CELL CULTURE MEDIA, CELL LINES, BUFFERS, AND REAGENTS MARKET, BY REGION, 2021-2028 (USD MILLION)
  • 6.6 OTHER PRODUCTS
    • TABLE 39 OTHER PRODUCTS MARKET, BY REGION, 2021-2028 (USD MILLION)
    • TABLE 40 NORTH AMERICA: OTHER PRODUCTS MARKET, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 41 EUROPE: OTHER PRODUCTS MARKET, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 42 ASIA PACIFIC: OTHER PRODUCTS MARKET, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 43 LATIN AMERICA: OTHER PRODUCTS MARKET, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 44 MIDDLE EAST & AFRICA: OTHER PRODUCTS MARKET, BY REGION, 2021-2028 (USD MILLION)

7 CONTINUOUS BIOPROCESSING MARKET, BY SCALE OF OPERATION

  • 7.1 INTRODUCTION
    • TABLE 45 CONTINUOUS BIOPROCESSING MARKET, BY SCALE OF OPERATION, 2021-2028 (USD MILLION)
  • 7.2 COMMERCIAL OPERATIONS
    • 7.2.1 GROWING FOCUS ON COST-REDUCTION OF BIOSIMILARS TO PROPEL MARKET
    • TABLE 46 CONTINUOUS BIOPROCESSING MARKET FOR COMMERCIAL OPERATIONS, BY REGION, 2021-2028 (USD MILLION)
    • TABLE 47 NORTH AMERICA: CONTINUOUS BIOPROCESSING MARKET FOR COMMERCIAL OPERATIONS, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 48 EUROPE: CONTINUOUS BIOPROCESSING MARKET FOR COMMERCIAL OPERATIONS, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 49 ASIA PACIFIC: CONTINUOUS BIOPROCESSING MARKET FOR COMMERCIAL OPERATIONS, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 50 LATIN AMERICA: CONTINUOUS BIOPROCESSING MARKET FOR COMMERCIAL OPERATIONS, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 51 MIDDLE EAST & AFRICA: CONTINUOUS BIOPROCESSING MARKET FOR COMMERCIAL OPERATIONS, BY REGION, 2021-2028 (USD MILLION)
  • 7.3 CLINICAL OPERATIONS
    • 7.3.1 INNOVATIONS IN R&D TESTING FOR THERAPEUTIC EFFICACY TO DRIVE MARKET
    • TABLE 52 CONTINUOUS BIOPROCESSING MARKET FOR CLINICAL OPERATIONS, BY REGION, 2021-2028 (USD MILLION)
    • TABLE 53 NORTH AMERICA: CONTINUOUS BIOPROCESSING MARKET FOR CLINICAL OPERATIONS, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 54 EUROPE: CONTINUOUS BIOPROCESSING MARKET FOR CLINICAL OPERATIONS, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 55 ASIA PACIFIC: CONTINUOUS BIOPROCESSING MARKET FOR CLINICAL OPERATIONS, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 56 LATIN AMERICA: CONTINUOUS BIOPROCESSING MARKET FOR CLINICAL OPERATIONS, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 57 MIDDLE EAST & AFRICA: CONTINUOUS BIOPROCESSING MARKET FOR CLINICAL OPERATIONS, BY REGION, 2021-2028 (USD MILLION)

8 CONTINUOUS BIOPROCESSING MARKET, BY PROCESS

  • 8.1 INTRODUCTION
    • TABLE 58 CONTINUOUS BIOPROCESSING MARKET, BY PROCESS, 2021-2028 (USD MILLION)
  • 8.2 DOWNSTREAM BIOPROCESS
    • 8.2.1 RISING TECHNOLOGICAL ADVANCEMENTS SUCH AS SPTFF AND MULTICOLUMN CHROMATOGRAPHY TO PROPEL MARKET
    • TABLE 59 CONTINUOUS BIOPROCESSING MARKET FOR DOWNSTREAM BIOPROCESS, BY REGION, 2021-2028 (USD MILLION)
    • TABLE 60 NORTH AMERICA: CONTINUOUS BIOPROCESSING MARKET FOR DOWNSTREAM BIOPROCESS, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 61 EUROPE: CONTINUOUS BIOPROCESSING MARKET FOR DOWNSTREAM BIOPROCESS, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 62 ASIA PACIFIC: CONTINUOUS BIOPROCESSING MARKET FOR DOWNSTREAM BIOPROCESS, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 63 LATIN AMERICA: CONTINUOUS BIOPROCESSING MARKET FOR DOWNSTREAM BIOPROCESS, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 64 MIDDLE EAST & AFRICA: CONTINUOUS BIOPROCESSING MARKET FOR DOWNSTREAM BIOPROCESS, BY REGION, 2021-2028 (USD MILLION)
  • 8.3 UPSTREAM BIOPROCESS
    • 8.3.1 ADOPTION OF PERFUSION TECHNOLOGY TO SUPPORT MARKET GROWTH
    • TABLE 65 CONTINUOUS BIOPROCESSING MARKET FOR UPSTREAM BIOPROCESS, BY REGION, 2021-2028 (USD MILLION)
    • TABLE 66 NORTH AMERICA: CONTINUOUS BIOPROCESSING MARKET FOR UPSTREAM BIOPROCESS, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 67 EUROPE: CONTINUOUS BIOPROCESSING MARKET FOR UPSTREAM BIOPROCESS, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 68 ASIA PACIFIC: CONTINUOUS BIOPROCESSING MARKET FOR UPSTREAM BIOPROCESS, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 69 LATIN AMERICA: CONTINUOUS BIOPROCESSING MARKET FOR UPSTREAM BIOPROCESS, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 70 MIDDLE EAST & AFRICA: CONTINUOUS BIOPROCESSING MARKET FOR UPSTREAM BIOPROCESS, BY REGION, 2021-2028 (USD MILLION)

9 CONTINUOUS BIOPROCESSING MARKET, BY APPLICATION

  • 9.1 INTRODUCTION
    • TABLE 71 CONTINUOUS BIOPROCESSING MARKET, BY APPLICATION, 2021-2028 (USD MILLION)
  • 9.2 MONOCLONAL ANTIBODIES
    • 9.2.1 GROWING FOCUS ON THERAPEUTIC APPLICATIONS TO PROPEL MARKET
    • TABLE 72 CONTINUOUS BIOPROCESSING MARKET FOR MONOCLONAL ANTIBODIES, BY REGION, 2021-2028 (USD MILLION)
    • TABLE 73 NORTH AMERICA: CONTINUOUS BIOPROCESSING MARKET FOR MONOCLONAL ANTIBODIES, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 74 EUROPE: CONTINUOUS BIOPROCESSING MARKET FOR MONOCLONAL ANTIBODIES, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 75 ASIA PACIFIC: CONTINUOUS BIOPROCESSING MARKET FOR MONOCLONAL ANTIBODIES, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 76 LATIN AMERICA: CONTINUOUS BIOPROCESSING MARKET FOR MONOCLONAL ANTIBODIES, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 77 MIDDLE EAST & AFRICA: CONTINUOUS BIOPROCESSING MARKET FOR MONOCLONAL ANTIBODIES, BY REGION, 2021-2028 (USD MILLION)
  • 9.3 VACCINES
    • 9.3.1 USE OF PERFUSION BIOREACTORS FOR VACCINE PRODUCTION TO DRIVE MARKET
    • TABLE 78 CONTINUOUS BIOPROCESSING MARKET FOR VACCINES, BY REGION, 2021-2028 (USD MILLION)
    • TABLE 79 NORTH AMERICA: CONTINUOUS BIOPROCESSING MARKET FOR VACCINES, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 80 EUROPE: CONTINUOUS BIOPROCESSING MARKET FOR VACCINES, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 81 ASIA PACIFIC: CONTINUOUS BIOPROCESSING MARKET FOR VACCINES, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 82 LATIN AMERICA: CONTINUOUS BIOPROCESSING MARKET FOR VACCINES, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 83 MIDDLE EAST & AFRICA: CONTINUOUS BIOPROCESSING MARKET FOR VACCINES, BY REGION, 2021-2028 (USD MILLION)
  • 9.4 CELL & GENE THERAPY
    • 9.4.1 INCREASING NUMBER OF CLINICAL TRIALS TO BOOST DEMAND
    • TABLE 84 CONTINUOUS BIOPROCESSING MARKET FOR CELL & GENE THERAPY, BY REGION, 2021-2028 (USD MILLION)
    • TABLE 85 NORTH AMERICA: CONTINUOUS BIOPROCESSING MARKET FOR CELL & GENE THERAPY, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 86 EUROPE: CONTINUOUS BIOPROCESSING MARKET FOR CELL & GENE THERAPY, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 87 ASIA PACIFIC: CONTINUOUS BIOPROCESSING MARKET FOR CELL & GENE THERAPY, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 88 LATIN AMERICA: CONTINUOUS BIOPROCESSING MARKET FOR CELL & GENE THERAPY, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 89 MIDDLE EAST & AFRICA: CONTINUOUS BIOPROCESSING MARKET FOR CELL & GENE THERAPY, BY REGION, 2021-2028 (USD MILLION)
  • 9.5 OTHER APPLICATIONS
    • TABLE 90 CONTINUOUS BIOPROCESSING MARKET FOR OTHER APPLICATIONS, BY REGION, 2021-2028 (USD MILLION)
    • TABLE 91 NORTH AMERICA: CONTINUOUS BIOPROCESSING MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 92 EUROPE: CONTINUOUS BIOPROCESSING MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 93 ASIA PACIFIC: CONTINUOUS BIOPROCESSING MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 94 LATIN AMERICA: CONTINUOUS BIOPROCESSING MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 95 MIDDLE EAST & AFRICA: CONTINUOUS BIOPROCESSING MARKET FOR OTHER APPLICATIONS, BY REGION, 2021-2028 (USD MILLION)

10 CONTINUOUS BIOPROCESSING MARKET, BY END USER

  • 10.1 INTRODUCTION
    • TABLE 96 CONTINUOUS BIOPROCESSING MARKET, BY END USER, 2021-2028 (USD MILLION)
  • 10.2 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES
    • 10.2.1 RISING DEMAND FOR BIOLOGICS AND BIOSIMILARS TO DRIVE MARKET
    • TABLE 97 CONTINUOUS BIOPROCESSING MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY REGION, 2021-2028 (USD MILLION)
    • TABLE 98 NORTH AMERICA: CONTINUOUS BIOPROCESSING MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 99 EUROPE: CONTINUOUS BIOPROCESSING MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 100 ASIA PACIFIC: CONTINUOUS BIOPROCESSING MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 101 LATIN AMERICA: CONTINUOUS BIOPROCESSING MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 102 MIDDLE EAST & AFRICA: CONTINUOUS BIOPROCESSING MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY REGION, 2021-2028 (USD MILLION)
  • 10.3 CONTRACT RESEARCH ORGANIZATIONS (CROS) AND CONTRACT MANUFACTURING ORGANIZATIONS (CMOS)
    • 10.3.1 RISING OUTSOURCING OF R&D SERVICES BY PHARMACEUTICAL & BIOPHARMACEUTICAL COMPANIES TO PROPEL MARKET
    • TABLE 103 CONTINUOUS BIOPROCESSING MARKET FOR CONTRACT RESEARCH ORGANIZATIONS AND CONTRACT MANUFACTURING ORGANIZATIONS, BY REGION, 2021-2028 (USD MILLION)
    • TABLE 104 NORTH AMERICA: CONTINUOUS BIOPROCESSING MARKET FOR CONTRACT RESEARCH ORGANIZATIONS AND CONTRACT MANUFACTURING ORGANIZATIONS, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 105 EUROPE: CONTINUOUS BIOPROCESSING MARKET FOR CONTRACT RESEARCH ORGANIZATIONS AND CONTRACT MANUFACTURING ORGANIZATIONS, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 106 ASIA PACIFIC: CONTINUOUS BIOPROCESSING MARKET FOR CONTRACT RESEARCH ORGANIZATIONS AND CONTRACT MANUFACTURING ORGANIZATIONS, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 107 LATIN AMERICA: CONTINUOUS BIOPROCESSING MARKET FOR CONTRACT RESEARCH ORGANIZATIONS AND CONTRACT MANUFACTURING ORGANIZATIONS, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 108 MIDDLE EAST & AFRICA: CONTINUOUS BIOPROCESSING MARKET FOR CONTRACT RESEARCH ORGANIZATIONS AND CONTRACT MANUFACTURING ORGANIZATIONS, BY REGION, 2021-2028 (USD MILLION)
  • 10.4 ACADEMIC & RESEARCH INSTITUTES
    • 10.4.1 COLLABORATIONS BETWEEN PHARMACEUTICAL MANUFACTURERS AND RESEARCH INSTITUTES TO SUPPORT MARKET GROWTH
    • TABLE 109 CONTINUOUS BIOPROCESSING MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY REGION, 2021-2028 (USD MILLION)
    • TABLE 110 NORTH AMERICA: CONTINUOUS BIOPROCESSING MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 111 EUROPE: CONTINUOUS BIOPROCESSING MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 112 ASIA PACIFIC: CONTINUOUS BIOPROCESSING MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 113 LATIN AMERICA: CONTINUOUS BIOPROCESSING MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 114 MIDDLE EAST & AFRICA: CONTINUOUS BIOPROCESSING MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY REGION, 2021-2028 (USD MILLION)

11 CONTINUOUS BIOPROCESSING MARKET, BY REGION

  • 11.1 INTRODUCTION
    • TABLE 115 CONTINUOUS BIOPROCESSING MARKET, BY REGION, 2021-2028 (USD MILLION)
  • 11.2 NORTH AMERICA
    • FIGURE 30 NORTH AMERICA: CONTINUOUS BIOPROCESSING MARKET SNAPSHOT
    • TABLE 116 NORTH AMERICA: CONTINUOUS BIOPROCESSING MARKET, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 117 NORTH AMERICA: CONTINUOUS BIOPROCESSING MARKET, BY PRODUCT, 2021-2028 (USD MILLION)
    • TABLE 118 NORTH AMERICA: CONTINUOUS BIOPROCESSING MARKET, BY SCALE OF OPERATION, 2021-2028 (USD MILLION)
    • TABLE 119 NORTH AMERICA: CONTINUOUS BIOPROCESSING MARKET, BY PROCESS, 2021-2028 (USD MILLION)
    • TABLE 120 NORTH AMERICA: CONTINUOUS BIOPROCESSING MARKET, BY APPLICATION, 2021-2028 (USD MILLION)
    • TABLE 121 NORTH AMERICA: CONTINUOUS BIOPROCESSING MARKET, BY END USER, 2021-2028 (USD MILLION)
    • 11.2.1 US
      • 11.2.1.1 High biopharmaceutical R&D spending to drive market
    • TABLE 122 US: CONTINUOUS BIOPROCESSING MARKET, BY PRODUCT, 2021-2028 (USD MILLION)
    • TABLE 123 US: CONTINUOUS BIOPROCESSING MARKET, BY SCALE OF OPERATION, 2021-2028 (USD MILLION)
    • TABLE 124 US: CONTINUOUS BIOPROCESSING MARKET, BY PROCESS, 2021-2028 (USD MILLION)
    • TABLE 125 US: CONTINUOUS BIOPROCESSING MARKET, BY APPLICATION, 2021-2028 (USD MILLION)
    • TABLE 126 US: CONTINUOUS BIOPROCESSING MARKET, BY END USER, 2021-2028 (USD MILLION)
    • 11.2.2 CANADA
      • 11.2.2.1 Growing establishment of biopharmaceutical manufacturing facilities to propel market
    • TABLE 127 CANADA: CONTINUOUS BIOPROCESSING MARKET, BY PRODUCT, 2021-2028 (USD MILLION)
    • TABLE 128 CANADA: CONTINUOUS BIOPROCESSING MARKET, BY SCALE OF OPERATION, 2021-2028 (USD MILLION)
    • TABLE 129 CANADA: CONTINUOUS BIOPROCESSING MARKET, BY PROCESS, 2021-2028 (USD MILLION)
    • TABLE 130 CANADA: CONTINUOUS BIOPROCESSING MARKET, BY APPLICATION, 2021-2028 (USD MILLION)
    • TABLE 131 CANADA: CONTINUOUS BIOPROCESSING MARKET, BY END USER, 2021-2028 (USD MILLION)
    • 11.2.3 NORTH AMERICA: RECESSION IMPACT
  • 11.3 EUROPE
    • TABLE 132 EUROPE: CONTINUOUS BIOPROCESSING MARKET, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 133 EUROPE: CONTINUOUS BIOPROCESSING MARKET, BY PRODUCT, 2021-2028 (USD MILLION)
    • TABLE 134 EUROPE: CONTINUOUS BIOPROCESSING MARKET, BY SCALE OF OPERATION, 2021-2028 (USD MILLION)
    • TABLE 135 EUROPE: CONTINUOUS BIOPROCESSING MARKET, BY PROCESS, 2021-2028 (USD MILLION)
    • TABLE 136 EUROPE: CONTINUOUS BIOPROCESSING MARKET, BY APPLICATION, 2021-2028 (USD MILLION)
    • TABLE 137 EUROPE: CONTINUOUS BIOPROCESSING MARKET, BY END USER, 2021-2028 (USD MILLION)
    • 11.3.1 GERMANY
      • 11.3.1.1 Increasing initiatives for life sciences research to boost demand
    • TABLE 138 GERMANY: CONTINUOUS BIOPROCESSING MARKET, BY PRODUCT, 2021-2028 (USD MILLION)
    • TABLE 139 GERMANY: CONTINUOUS BIOPROCESSING MARKET, BY SCALE OF OPERATION, 2021-2028 (USD MILLION)
    • TABLE 140 GERMANY: CONTINUOUS BIOPROCESSING MARKET, BY PROCESS, 2021-2028 (USD MILLION)
    • TABLE 141 GERMANY: CONTINUOUS BIOPROCESSING MARKET, BY APPLICATION, 2021-2028 (USD MILLION)
    • TABLE 142 GERMANY: CONTINUOUS BIOPROCESSING MARKET, BY END USER, 2021-2028 (USD MILLION)
    • 11.3.2 UK
      • 11.3.2.1 Favorable government support for biotech clusters to propel market
    • TABLE 143 UK: CONTINUOUS BIOPROCESSING MARKET, BY PRODUCT, 2021-2028 (USD MILLION)
    • TABLE 144 UK: CONTINUOUS BIOPROCESSING MARKET, BY SCALE OF OPERATION, 2021-2028 (USD MILLION)
    • TABLE 145 UK: CONTINUOUS BIOPROCESSING MARKET, BY PROCESS, 2021-2028 (USD MILLION)
    • TABLE 146 UK: CONTINUOUS BIOPROCESSING MARKET, BY APPLICATION, 2021-2028 (USD MILLION)
    • TABLE 147 UK: CONTINUOUS BIOPROCESSING MARKET, BY END USER, 2021-2028 (USD MILLION)
    • 11.3.3 FRANCE
      • 11.3.3.1 Rising demand for mAbs and biologics to drive market
    • TABLE 148 FRANCE: CONTINUOUS BIOPROCESSING MARKET, BY PRODUCT, 2021-2028 (USD MILLION)
    • TABLE 149 FRANCE: CONTINUOUS BIOPROCESSING MARKET, BY SCALE OF OPERATION, 2021-2028 (USD MILLION)
    • TABLE 150 FRANCE: CONTINUOUS BIOPROCESSING MARKET, BY PROCESS, 2021-2028 (USD MILLION)
    • TABLE 151 FRANCE: CONTINUOUS BIOPROCESSING MARKET, BY APPLICATION, 2021-2028 (USD MILLION)
    • TABLE 152 FRANCE: CONTINUOUS BIOPROCESSING MARKET, BY END USER, 2021-2028 (USD MILLION)
    • 11.3.4 ITALY
      • 11.3.4.1 Growth in pharma & biopharma industries to boost demand
    • TABLE 153 ITALY: CONTINUOUS BIOPROCESSING MARKET, BY PRODUCT, 2021-2028 (USD MILLION)
    • TABLE 154 ITALY: CONTINUOUS BIOPROCESSING MARKET, BY SCALE OF OPERATION, 2021-2028 (USD MILLION)
    • TABLE 155 ITALY: CONTINUOUS BIOPROCESSING MARKET, BY PROCESS, 2021-2028 (USD MILLION)
    • TABLE 156 ITALY: CONTINUOUS BIOPROCESSING MARKET, BY APPLICATION, 2021-2028 (USD MILLION)
    • TABLE 157 ITALY: CONTINUOUS BIOPROCESSING MARKET, BY END USER, 2021-2028 (USD MILLION)
    • 11.3.5 SPAIN
      • 11.3.5.1 Increasing R&D funding by academic institutes to support market growth
    • TABLE 158 SPAIN: CONTINUOUS BIOPROCESSING MARKET, BY PRODUCT, 2021-2028 (USD MILLION)
    • TABLE 159 SPAIN: CONTINUOUS BIOPROCESSING MARKET, BY SCALE OF OPERATION, 2021-2028 (USD MILLION)
    • TABLE 160 SPAIN: CONTINUOUS BIOPROCESSING MARKET, BY PROCESS, 2021-2028 (USD MILLION)
    • TABLE 161 SPAIN: CONTINUOUS BIOPROCESSING MARKET, BY APPLICATION, 2021-2028 (USD MILLION)
    • TABLE 162 SPAIN: CONTINUOUS BIOPROCESSING MARKET, BY END USER, 2021-2028 (USD MILLION)
    • 11.3.6 REST OF EUROPE
    • TABLE 163 REST OF EUROPE: CONTINUOUS BIOPROCESSING MARKET, BY PRODUCT, 2021-2028 (USD MILLION)
    • TABLE 164 REST OF EUROPE: CONTINUOUS BIOPROCESSING MARKET, BY SCALE OF OPERATION, 2021-2028 (USD MILLION)
    • TABLE 165 REST OF EUROPE: CONTINUOUS BIOPROCESSING MARKET, BY PROCESS, 2021-2028 (USD MILLION)
    • TABLE 166 REST OF EUROPE: CONTINUOUS BIOPROCESSING MARKET, BY APPLICATION, 2021-2028 (USD MILLION)
    • TABLE 167 REST OF EUROPE: CONTINUOUS BIOPROCESSING MARKET, BY END USER, 2021-2028 (USD MILLION)
    • 11.3.7 EUROPE: RECESSION IMPACT
  • 11.4 ASIA PACIFIC
    • FIGURE 31 ASIA PACIFIC: CONTINUOUS BIOPROCESSING MARKET SNAPSHOT
    • TABLE 168 ASIA PACIFIC: CONTINUOUS BIOPROCESSING MARKET, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 169 ASIA PACIFIC: CONTINUOUS BIOPROCESSING MARKET, BY PRODUCT, 2021-2028 (USD MILLION)
    • TABLE 170 ASIA PACIFIC: CONTINUOUS BIOPROCESSING MARKET, BY SCALE OF OPERATION, 2021-2028 (USD MILLION)
    • TABLE 171 ASIA PACIFIC: CONTINUOUS BIOPROCESSING MARKET, BY PROCESS, 2021-2028 (USD MILLION)
    • TABLE 172 ASIA PACIFIC: CONTINUOUS BIOPROCESSING MARKET, BY APPLICATION, 2021-2028 (USD MILLION)
    • TABLE 173 ASIA PACIFIC: CONTINUOUS BIOPROCESSING MARKET, BY END USER, 2021-2028 (USD MILLION)
    • 11.4.1 CHINA
      • 11.4.1.1 Government support and rising private investments to drive market growth
    • TABLE 174 CHINA: CONTINUOUS BIOPROCESSING MARKET, BY PRODUCT, 2021-2028 (USD MILLION)
    • TABLE 175 CHINA: CONTINUOUS BIOPROCESSING MARKET, BY SCALE OF OPERATION, 2021-2028 (USD MILLION)
    • TABLE 176 CHINA: CONTINUOUS BIOPROCESSING MARKET, BY PROCESS, 2021-2028 (USD MILLION)
    • TABLE 177 CHINA: CONTINUOUS BIOPROCESSING MARKET, BY APPLICATION, 2021-2028 (USD MILLION)
    • TABLE 178 CHINA: CONTINUOUS BIOPROCESSING MARKET, BY END USER, 2021-2028 (USD MILLION)
    • 11.4.2 JAPAN
      • 11.4.2.1 Stringent regulatory guidelines for pharmaceutical drug safety to support market growth
    • TABLE 179 JAPAN: CONTINUOUS BIOPROCESSING MARKET, BY PRODUCT, 2021-2028 (USD MILLION)
    • TABLE 180 JAPAN: CONTINUOUS BIOPROCESSING MARKET, BY SCALE OF OPERATION, 2021-2028 (USD MILLION)
    • TABLE 181 JAPAN: CONTINUOUS BIOPROCESSING MARKET, BY PROCESS, 2021-2028 (USD MILLION)
    • TABLE 182 JAPAN: CONTINUOUS BIOPROCESSING MARKET, BY APPLICATION, 2021-2028 (USD MILLION)
    • TABLE 183 JAPAN: CONTINUOUS BIOPROCESSING MARKET, BY END USER, 2021-2028 (USD MILLION)
    • 11.4.3 INDIA
      • 11.4.3.1 Growth in pharmaceutical industry to boost demand
    • TABLE 184 INDIA: CONTINUOUS BIOPROCESSING MARKET, BY PRODUCT, 2021-2028 (USD MILLION)
    • TABLE 185 INDIA: CONTINUOUS BIOPROCESSING MARKET, BY SCALE OF OPERATION, 2021-2028 (USD MILLION)
    • TABLE 186 INDIA: CONTINUOUS BIOPROCESSING MARKET, BY PROCESS, 2021-2028 (USD MILLION)
    • TABLE 187 INDIA: CONTINUOUS BIOPROCESSING MARKET, BY APPLICATION, 2021-2028 (USD MILLION)
    • TABLE 188 INDIA: CONTINUOUS BIOPROCESSING MARKET, BY END USER, 2021-2028 (USD MILLION)
    • 11.4.4 SOUTH KOREA
      • 11.4.4.1 Rising focus on quality manufacturing practices to drive market
    • TABLE 189 SOUTH KOREA: CONTINUOUS BIOPROCESSING MARKET, BY PRODUCT, 2021-2028 (USD MILLION)
    • TABLE 190 SOUTH KOREA: CONTINUOUS BIOPROCESSING MARKET, BY SCALE OF OPERATION, 2021-2028 (USD MILLION)
    • TABLE 191 SOUTH KOREA: CONTINUOUS BIOPROCESSING MARKET, BY PROCESS, 2021-2028 (USD MILLION)
    • TABLE 192 SOUTH KOREA: CONTINUOUS BIOPROCESSING MARKET, BY APPLICATION, 2021-2028 (USD MILLION)
    • TABLE 193 SOUTH KOREA: CONTINUOUS BIOPROCESSING MARKET, BY END USER, 2021-2028 (USD MILLION)
    • 11.4.5 REST OF ASIA PACIFIC
    • TABLE 194 REST OF ASIA PACIFIC: CONTINUOUS BIOPROCESSING MARKET, BY PRODUCT, 2021-2028 (USD MILLION)
    • TABLE 195 REST OF ASIA PACIFIC: CONTINUOUS BIOPROCESSING MARKET, BY SCALE OF OPERATION, 2021-2028 (USD MILLION)
    • TABLE 196 REST OF ASIA PACIFIC: CONTINUOUS BIOPROCESSING MARKET, BY PROCESS, 2021-2028 (USD MILLION)
    • TABLE 197 REST OF ASIA PACIFIC: CONTINUOUS BIOPROCESSING MARKET, BY APPLICATION, 2021-2028 (USD MILLION)
    • TABLE 198 REST OF ASIA PACIFIC: CONTINUOUS BIOPROCESSING MARKET, BY END USER, 2021-2028 (USD MILLION)
    • 11.4.6 ASIA PACIFIC: RECESSION IMPACT
  • 11.5 LATIN AMERICA
    • TABLE 199 LATIN AMERICA: CONTINUOUS BIOPROCESSING MARKET, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 200 LATIN AMERICA: CONTINUOUS BIOPROCESSING MARKET, BY PRODUCT, 2021-2028 (USD MILLION)
    • TABLE 201 LATIN AMERICA: CONTINUOUS BIOPROCESSING MARKET, BY SCALE OF OPERATION, 2021-2028 (USD MILLION)
    • TABLE 202 LATIN AMERICA: CONTINUOUS BIOPROCESSING MARKET, BY PROCESS, 2021-2028 (USD MILLION)
    • TABLE 203 LATIN AMERICA: CONTINUOUS BIOPROCESSING MARKET, BY APPLICATION, 2021-2028 (USD MILLION)
    • TABLE 204 LATIN AMERICA: CONTINUOUS BIOPROCESSING MARKET, BY END USER, 2021-2028 (USD MILLION)
    • 11.5.1 BRAZIL
      • 11.5.1.1 Rising focus on cell & therapy manufacturing to support market
    • TABLE 205 BRAZIL: CONTINUOUS BIOPROCESSING MARKET, BY PRODUCT, 2021-2028 (USD MILLION)
    • TABLE 206 BRAZIL: CONTINUOUS BIOPROCESSING MARKET, BY SCALE OF OPERATION, 2021-2028 (USD MILLION)
    • TABLE 207 BRAZIL: CONTINUOUS BIOPROCESSING MARKET, BY PROCESS, 2021-2028 (USD MILLION)
    • TABLE 208 BRAZIL: CONTINUOUS BIOPROCESSING MARKET, BY APPLICATION, 2021-2028 (USD MILLION)
    • TABLE 209 BRAZIL: CONTINUOUS BIOPROCESSING MARKET, BY END USER, 2021-2028 (USD MILLION)
    • 11.5.2 MEXICO
      • 11.5.2.1 Increasing expansion of pharmaceutical companies to support market growth
    • TABLE 210 MEXICO: CONTINUOUS BIOPROCESSING MARKET, BY PRODUCT, 2021-2028 (USD MILLION)
    • TABLE 211 MEXICO: CONTINUOUS BIOPROCESSING MARKET, BY SCALE OF OPERATION, 2021-2028 (USD MILLION)
    • TABLE 212 MEXICO: CONTINUOUS BIOPROCESSING MARKET, BY PROCESS, 2021-2028 (USD MILLION)
    • TABLE 213 MEXICO: CONTINUOUS BIOPROCESSING MARKET, BY APPLICATION, 2021-2028 (USD MILLION)
    • TABLE 214 MEXICO: CONTINUOUS BIOPROCESSING MARKET, BY END USER, 2021-2028 (USD MILLION)
    • 11.5.3 REST OF LATIN AMERICA
    • TABLE 215 REST OF LATIN AMERICA: CONTINUOUS BIOPROCESSING MARKET, BY PRODUCT, 2021-2028 (USD MILLION)
    • TABLE 216 REST OF LATIN AMERICA: CONTINUOUS BIOPROCESSING MARKET, BY SCALE OF OPERATION, 2021-2028 (USD MILLION)
    • TABLE 217 REST OF LATIN AMERICA: CONTINUOUS BIOPROCESSING MARKET, BY PROCESS, 2021-2028 (USD MILLION)
    • TABLE 218 REST OF LATIN AMERICA: CONTINUOUS BIOPROCESSING MARKET, BY APPLICATION, 2021-2028 (USD MILLION)
    • TABLE 219 REST OF LATIN AMERICA: CONTINUOUS BIOPROCESSING MARKET, BY END USER, 2021-2028 (USD MILLION)
    • 11.5.4 LATIN AMERICA: RECESSION IMPACT
  • 11.6 MIDDLE EAST & AFRICA
    • TABLE 220 MIDDLE EAST & AFRICA: CONTINUOUS BIOPROCESSING MARKET, BY REGION, 2021-2028 (USD MILLION)
    • TABLE 221 MIDDLE EAST & AFRICA: CONTINUOUS BIOPROCESSING MARKET, BY PRODUCT, 2021-2028 (USD MILLION)
    • TABLE 222 MIDDLE EAST & AFRICA: CONTINUOUS BIOPROCESSING MARKET, BY SCALE OF OPERATION, 2021-2028 (USD MILLION)
    • TABLE 223 MIDDLE EAST & AFRICA: CONTINUOUS BIOPROCESSING MARKET, BY PROCESS, 2021-2028 (USD MILLION)
    • TABLE 224 MIDDLE EAST & AFRICA: CONTINUOUS BIOPROCESSING MARKET, BY APPLICATION, 2021-2028 (USD MILLION)
    • TABLE 225 MIDDLE EAST & AFRICA: CONTINUOUS BIOPROCESSING MARKET, BY END USER, 2021-2028 (USD MILLION)
    • 11.6.1 MIDDLE EAST
      • 11.6.1.1 Increasing demand for biopharmaceutical drugs to drive market
    • TABLE 226 MIDDLE EAST: CONTINUOUS BIOPROCESSING MARKET, BY PRODUCT, 2021-2028 (USD MILLION)
    • TABLE 227 MIDDLE EAST: CONTINUOUS BIOPROCESSING MARKET, BY SCALE OF OPERATION, 2021-2028 (USD MILLION)
    • TABLE 228 MIDDLE EAST: CONTINUOUS BIOPROCESSING MARKET, BY PROCESS, 2021-2028 (USD MILLION)
    • TABLE 229 MIDDLE EAST: CONTINUOUS BIOPROCESSING MARKET, BY APPLICATION, 2021-2028 (USD MILLION)
    • TABLE 230 MIDDLE EAST: CONTINUOUS BIOPROCESSING MARKET, BY END USER, 2021-2028 (USD MILLION)
    • 11.6.2 AFRICA
      • 11.6.2.1 Favorable initiatives for R&D investments to support market growth
    • TABLE 231 AFRICA: CONTINUOUS BIOPROCESSING MARKET, BY PRODUCT, 2021-2028 (USD MILLION)
    • TABLE 232 AFRICA: CONTINUOUS BIOPROCESSING MARKET, BY SCALE OF OPERATION, 2021-2028 (USD MILLION)
    • TABLE 233 AFRICA: CONTINUOUS BIOPROCESSING MARKET, BY PROCESS, 2021-2028 (USD MILLION)
    • TABLE 234 AFRICA: CONTINUOUS BIOPROCESSING MARKET, BY APPLICATION, 2021-2028 (USD MILLION)
    • TABLE 235 AFRICA: CONTINUOUS BIOPROCESSING MARKET, BY END USER, 2021-2028 (USD MILLION)
    • 11.6.3 MIDDLE EAST & AFRICA: RECESSION IMPACT

12 COMPETITIVE LANDSCAPE

  • 12.1 OVERVIEW
  • 12.2 KEY PLAYER STRATEGIES/RIGHT TO WIN
  • 12.3 REVENUE SHARE ANALYSIS
    • FIGURE 32 REVENUE SHARE ANALYSIS FOR KEY PLAYERS (2018-2022)
  • 12.4 MARKET SHARE ANALYSIS
    • FIGURE 33 CONTINUOUS BIOPROCESSING MARKET: MARKET SHARE ANALYSIS OF KEY PLAYERS (2022)
    • TABLE 236 CONTINUOUS BIOPROCESSING MARKET: INTENSITY OF COMPETITIVE RIVALRY
  • 12.5 COMPANY EVALUATION MATRIX
    • 12.5.1 STARS
    • 12.5.2 PERVASIVE PLAYERS
    • 12.5.3 EMERGING LEADERS
    • 12.5.4 PARTICIPANTS
    • FIGURE 34 COMPANY EVALUATION MATRIX FOR KEY PLAYERS (2022)
    • 12.5.5 COMPANY FOOTPRINT ANALYSIS
    • TABLE 237 CONTINUOUS BIOPROCESSING MARKET: OVERALL COMPANY FOOTPRINT (2022)
    • 12.5.6 PRODUCT FOOTPRINT OF COMPANIES
    • TABLE 238 CONTINUOUS BIOPROCESSING MARKET: PRODUCT FOOTPRINT ANALYSIS
    • 12.5.7 REGIONAL FOOTPRINT OF COMPANIES
    • TABLE 239 CONTINUOUS BIOPROCESSING MARKET: REGIONAL FOOTPRINT ANALYSIS
  • 12.6 START-UP/SME EVALUATION MATRIX
    • 12.6.1 PROGRESSIVE COMPANIES
    • 12.6.2 RESPONSIVE COMPANIES
    • 12.6.3 DYNAMIC COMPANIES
    • 12.6.4 STARTING BLOCKS
    • FIGURE 35 COMPANY EVALUATION MATRIX FOR START-UP/SMES (2022)
    • 12.6.5 COMPETITIVE BENCHMARKING OF START-UP/SMES
    • TABLE 240 CONTINUOUS BIOPROCESSING MARKET: DETAILED LIST OF KEY START-UP/SME PLAYERS
    • TABLE 241 CONTINUOUS BIOPROCESSING MARKET: COMPETITIVE BENCHMARKING OF START-UPS/SMES
  • 12.7 COMPETITIVE SCENARIOS AND TRENDS
    • 12.7.1 PRODUCT LAUNCHES
    • TABLE 242 CONTINUOUS BIOPROCESSING MARKET: PRODUCT LAUNCHES & APPROVALS (JANUARY 2020-OCTOBER 2023)
    • 12.7.2 DEALS
    • TABLE 243 CONTINUOUS BIOPROCESSING MARKET: DEALS (JANUARY 2020-OCTOBER 2023)
    • 12.7.3 OTHER DEVELOPMENTS
    • TABLE 244 CONTINUOUS BIOPROCESSING MARKET: OTHER DEVELOPMENTS (JANUARY 2020-OCTOBER 2023)

13 COMPANY PROFILES

  • (Business Overview, Products/Solutions/Services Offered, Recent Developments, MnM view (Key strengths/Right to win, Strategic choices made, Weakness/competitive threats)**
  • 13.1 KEY PLAYERS
    • 13.1.1 DANAHER CORPORATION
    • TABLE 245 DANAHER CORPORATION: BUSINESS OVERVIEW
    • FIGURE 36 DANAHER CORPORATION: COMPANY SNAPSHOT (2022)
    • 13.1.2 SARTORIUS AG
    • TABLE 246 SARTORIUS AG: BUSINESS OVERVIEW
    • FIGURE 37 SARTORIUS AG: COMPANY SNAPSHOT (2022)
    • 13.1.3 THERMO FISHER SCIENTIFIC INC.
    • TABLE 247 THERMO FISHER SCIENTIFIC INC.: BUSINESS OVERVIEW
    • FIGURE 38 THERMO FISHER SCIENTIFIC INC.: COMPANY SNAPSHOT (2022)
    • 13.1.4 REPLIGEN CORPORATION
    • TABLE 248 REPLIGEN CORPORATION: BUSINESS OVERVIEW
    • FIGURE 39 REPLIGEN CORPORATION: COMPANY SNAPSHOT (2022)
    • 13.1.5 MERCK KGAA
    • TABLE 249 MERCK KGAA: BUSINESS OVERVIEW
    • FIGURE 40 MERCK KGAA: COMPANY SNAPSHOT (2022)
    • 13.1.6 3M COMPANY
    • TABLE 250 3M COMPANY: BUSINESS OVERVIEW
    • FIGURE 41 3M COMPANY: COMPANY SNAPSHOT (2022)
    • 13.1.7 GETINGE AB
    • TABLE 251 GETINGE AB: BUSINESS OVERVIEW
    • FIGURE 42 GETINGE AB: COMPANY SNAPSHOT (2022)
    • 13.1.8 EPPENDORF SE
    • TABLE 252 EPPENDORF SE: BUSINESS OVERVIEW
    • FIGURE 43 EPPENDORF SE: COMPANY SNAPSHOT (2022)
    • 13.1.9 CORNING INCORPORATED
    • TABLE 253 CORNING INCORPORATED: BUSINESS OVERVIEW
    • FIGURE 44 CORNING INCORPORATED: COMPANY SNAPSHOT (2022)
    • 13.1.10 ENTEGRIS
    • TABLE 254 ENTEGRIS: BUSINESS OVERVIEW
    • FIGURE 45 ENTEGRIS: COMPANY SNAPSHOT (2022)
    • 13.1.11 FUJIFILM HOLDINGS CORPORATION
    • TABLE 255 FUJIFILM HOLDINGS CORPORATION: BUSINESS OVERVIEW
    • FIGURE 46 FUJIFILM HOLDINGS CORPORATION: COMPANY SNAPSHOT (2022)
    • 13.1.12 MEISSNER FILTRATION PRODUCTS, INC.
    • TABLE 256 MEISSNER FILTRATION PRODUCTS, INC.: BUSINESS OVERVIEW
    • 13.1.13 KUHNER AG
    • TABLE 257 KUHNER AG: BUSINESS OVERVIEW
    • 13.1.14 ESCO LIFESCIENCES GROUP
    • TABLE 258 ESCO LIFESCIENCES GROUP: BUSINESS OVERVIEW
    • 13.1.15 SATAKE MULTIMIX CORPORATION
    • TABLE 259 SATAKE MULTIMIX CORPORATION: BUSINESS OVERVIEW
  • 13.2 OTHER PLAYERS
    • 13.2.1 BIONET
    • 13.2.2 STOBBE GROUP
    • 13.2.3 BBI-BIOTECH GMBH
    • 13.2.4 OMNIBRX BIOTECHNOLOGIES
    • 13.2.5 CELL CULTURE COMPANY, LLC
    • 13.2.6 PIERRE GUERIN
    • 13.2.7 SOLIDA BIOTECH GMBH
    • 13.2.8 ZELLWERK GMBH
    • 13.2.9 3D BIOTEK, LLC
    • 13.2.10 FIBERCELL SYSTEMS INC.
  • *Details on Business Overview, Products/Solutions/Services Offered, Recent Developments, MnM view (Key strengths/Right to win, Strategic choices made, Weakness/competitive threats)** might not be captured in case of unlisted companies.

14 APPENDIX

  • 14.1 DISCUSSION GUIDE
  • 14.2 KNOWLEDGESTORE: MARKETSANDMARKETS' SUBSCRIPTION PORTAL
  • 14.3 CUSTOMIZATION OPTIONS
  • 14.4 RELATED REPORTS
  • 14.5 AUTHOR DETAILS